Chronic Thyroid DiseaseNCT07247981
T1 Tissue Mapping as a Non Invasive Biomarker for Quantification of Chronic Thyroid Related Microscopic Myocardial Fibrosis.
An observational study of Chronic Thyroid Disease, run by Assiut University.
Trial summary
CMR T1 tissue mapping helps in detection and quantification of the microscopic myocardial fibrosis and is more accurate and non invasive maneuver. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Thyroid Disease
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Hypo and hyperthyroidism in both genders.
Who may be able to join
- patients with chronic thyroid disease.
Who cannot join
- patients with other chronic illnesses ( diabetes, hypertension, .. etc).
- patients received neck radiation therapy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
CMR T1 tissue mapping helps in detection and quantification of the microscopic myocardial fibrosis and is more accurate and non invasive maneuver.
Read the detailed description
Chronic thyroid diseased patients either hypo or hyperthyroidism may develop arrhythmias or even atrial fibrillation which is worrisome. And since early detection provides the early management, T1 tissue mapping of the heart provides accurate quantification of the myocardial fibrosis throughout the imaged organ.
- Conditions
- Chronic Thyroid Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Myocardial fibrosis
Detection and quantification of myocardial fibrosis.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2025
- Study start1 Jan 2026 (estimated)
- Primary completionJan 2026 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Thyroid DiseaseStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lina Mohamed Farid, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07247981
- Sponsor's protocol ID
- CMR T1 tissue mapping
- Status last verified
- Nov 2025
- First submitted
- 18 Nov 2025
- Last updated
- 25 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- T1 Tissue Mapping as a Non Invasive Biomarker for Quantification of Chronic Thyroid Related Microscopic Myocardial Fibrosis.
- ClinicalTrials.gov ID
- NCT07247981
- Acronym / sponsor ID
- CMR T1 tissue mapping
- Conditions
- Chronic Thyroid Disease
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 25 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CMR T1 tissue mapping helps in detection and quantification of the microscopic myocardial fibrosis and is more accurate and non invasive maneuver.
Detailed description
Chronic thyroid diseased patients either hypo or hyperthyroidism may develop arrhythmias or even atrial fibrillation which is worrisome. And since early detection provides the early management, T1 tissue mapping of the heart provides accurate quantification of the myocardial fibrosis throughout the imaged organ.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Hypo and hyperthyroidism in both genders.
Key inclusion criteria (1 listed)
- patients with chronic thyroid disease.
Key exclusion criteria (2 listed)
- patients with other chronic illnesses ( diabetes, hypertension, .. etc).
- patients received neck radiation therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Myocardial fibrosis
Time frame: 1 year
Detection and quantification of myocardial fibrosis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2025.
Related trials for Chronic Thyroid Disease
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingPhase 3
Treatment of Chronic Thyroid Eye Disease With MHB018A
Thyroid Eye Disease, TED
Not yet recruitingObservational study
Role of Total Thyroidectomy in Relieving Local Symptoms in Hashimoto's Thyroiditis
Hashimoto Thyroiditis, Goiter
Active, not recruitingPhase 3
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Thyroid Eye Disease (TED)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Thyroid Disease, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lina M Farid, MSc (01063455559, Lina.m.farid@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Myocardial fibrosis (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.